Mood Stabilizers

Mood stabilizers are psychotropic drugs used to treat and prevent the mood episodes of bipolar disorder, dampening both manic and depressive swings. Lithium is the prototypical mood stabilizer; the group as used in practice also includes certain anticonvulsants and some second-generation antipsychotics that have mood-stabilising effects.

Definition

Mood stabilizers are drugs used to reduce and prevent the mood episodes of bipolar disorder; lithium is the classic agent, and the functional class also encompasses certain anticonvulsants and some antipsychotics used for mood stabilisation.

Scope

This entry describes what mood stabilizers are, the central role of lithium, the comparative evidence for antimanic and prophylactic effects, and the monitoring that the narrow therapeutic range of lithium entails. It is a reference-educational topic for mental health nursing and does not provide dosing or individualised treatment guidance.

Key concepts

• Lithium
• Anticonvulsant mood stabilizers
• Antimanic effect
• Maintenance and relapse prevention
• Narrow therapeutic index of lithium
• Serum level and toxicity monitoring

Mechanisms

Lithium's precise mechanism of action remains incompletely understood, but it is thought to act on intracellular signalling pathways involved in neuronal stability; the anticonvulsant mood stabilizers act through effects on ion channels and neurotransmission, and some antipsychotics contribute mood-stabilising effects through their receptor activity. A defining practical feature of lithium is its narrow therapeutic index: the gap between effective and toxic serum concentrations is small, so its use is characterised by the need for monitoring. Comparative evidence supports lithium and several other agents in acute mania, and lithium is also associated with prevention of suicide in mood disorders.

Clinical relevance

For nurses, mood stabilizers are central to the care of people with bipolar disorder across acute and maintenance phases, and understanding the class supports administration, awareness of lithium's narrow therapeutic range and signs of toxicity, the importance of serum-level and physical-health monitoring, and patient education about adherence. The content here describes the class for reference and education and is not a basis for prescribing or for individual treatment decisions.

Epidemiology

Lithium has remained a reference treatment for bipolar disorder for decades, and comparative meta-analyses have examined the relative efficacy of antimanic agents and lithium's association with reduced suicide risk. Long-term use also requires attention to renal, thyroid, and other physical health effects.

History

Lithium's mood-stabilising effect in mania was reported by John Cade in 1949, and after subsequent controlled study it became established as the prototypical mood stabilizer. Anticonvulsants such as valproate and carbamazepine were later adopted for mood stabilisation, and some second-generation antipsychotics were added to the functional class, while comparative meta-analyses in the 2010s clarified relative antimanic efficacy and lithium's role in suicide prevention.

Debates

Does lithium specifically reduce suicide risk in mood disorders?

Systematic review and meta-analysis support an association between lithium treatment and reduced risk of suicide and self-harm in mood disorders, a finding that informs ongoing discussion of lithium's distinctive place among mood stabilizers.

Key figures

• Andrea Cipriani
• John R. Geddes
• Christoph U. Correll
• Stephen M. Stahl

Seminal works

• cipriani-2013
• cipriani-2011

Frequently asked questions

Why does lithium require regular blood-level monitoring?

Lithium has a narrow therapeutic index, meaning the difference between an effective level and a toxic level is small. Periodic measurement of serum levels and physical-health parameters is used to keep treatment within a safe range. Specific monitoring is an individual clinical matter beyond the scope of this reference entry.

Are mood stabilizers only lithium?

No. Lithium is the prototypical mood stabilizer, but the functional class also includes certain anticonvulsants and some second-generation antipsychotics that have mood-stabilising effects in bipolar disorder.